Efficacy of tislelizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer and its influence on serum tumor markers
Objective To explore the clinical efficacy of tislelizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC)and its influence on serum tumor markers.Methods The clinical data of 106 patients with advanced non-small cell lung cancer were retrospectively analyzed,and they were divided into a control group(gemcitabine monotherapy)and an observation group(gemcitabine combined with tislelizumab)according to different treatment methods,with 53 cases in each group.Observation and comparison were made on clinical efficacy,occurrence of adverse drug reactions,36-item short-form health survey(SF-36)score,carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),and neuron-specific enolase(NSE)levels before and after treatment.Results The remission rate of disease in the observation group(92.5%)was significantly higher than that in the control group(77.4%)(P<0.05).In the observation group,the SF-36 score was(48.57±3.56)points before treatment and(86.34±5.32)points after treatment.In the control group,the SF-36 score was(48.61±3.58)points before treatment and(63.28±4.63)points after treatment.Compared with before treatment,the SF-36 scores in both groups improved significantly after treatment,and the SF-36 score in the observation group was significantly higher than that in the control group after treatment(P<0.05).In the observation group,CA125 was(105.86±5.29)U/ml,CEA was(65.76±0.23)μg/L,and NSE was(38.56±2.30)ng/ml before treatment,and after treatment,CA125 was(32.92±2.38)U/ml,CEA was(16.85±2.23)μg/L,and NSE was(6.54±1.67)ng/ml.In the control group,CA125 was(105.88±5.30)U/ml,CEA was(65.79±0.25)μg/L,and NSE was(38.62±2.31)ng/ml before treatment,and after treatment,CA125 was(63.32±2.31)U/ml,CEA was(29.27±2.29)μg/L,and NSE was(22.15±1.88)ng/ml.Before treatment,there was no significant difference in serum CA125,CEA and NSE levels between the two groups(P>0.05).Compared with before treatment,the serum CA125,CEA and NSE levels in both groups decreased after treatment;compared with the control group,the serum CA125,CEA and NSE levels in the observation group were significantly low after treatment(P<0.05).During treatment,the incidence of adverse drug reactions in the observation group(3.8%)was significantly lower than that in the control group(20.8%)(P<0.05).Conclusion In patients with advanced lung cancer,the combination of tislelizumab and chemotherapy can significantly improve the clinical symptoms of patients,significantly increase the total clinical response rate,reduce the level of serum tumor markers,improve the quality of life of patients,and significantly reduce the adverse drug reactions during treatment.
NETL
NSTL
万方数据
维普
